1 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 WELCOME ELLIE BRUNI Publishing Director TWENTYFOURSEVENBIOPHARMA Introducing the 2026 launch issue of 24/7 Biopharma, arriving during DCAT Week 2026 in New York. As proud members and media partners of DCAT, we’re excited to share a collection of stories across our digital platforms and website that reflect the people and progress influencing biopharma today. Inside you’ll find timely news, hands-on features. We celebrate real breakthroughs, from expanding mRNA and gene-therapy pipelines to AI-powered discovery and continued investment in advanced biologics manufacturing. You’ll read case studies from teams turning new platforms into treatments, interviews with leaders navigating complex partnerships, and technical pieces on manufacturing approaches that aim to cut costs and speed delivery to patients. At the same time, the industry faces hard realities. Supply chains remain fragile, raw-material sourcing is tangled by geopolitical strain, and workforce gaps complicate both R&D and production. Recent trade and regulatory moves are only part of the picture, they raise questions about tariff exposure and broader market uncertainty. Now is the moment for companies to pressure-test sourcing plans, lean into AI-driven forecasting, and build practical scenario plans. Resilience and clear, disciplined planning will matter more than ever as trade dynamics shift. In conclusion, as we reflect on our progress and look toward the future, let us focus on fostering resilience across the industry. Embracing innovation, navigating geopolitical challenges, and prioritizing collaboration will be essential to driving transformative change in biopharma. Together, we can ensure that our advancements lead to better health outcomes for patients around the world. We look forward to engaging discussions and shared insights during this important week. We hope this issue informs and inspires you. If you’d like to contribute an editorial, commentary, or news tip, please send submissions to editor@247biopharma.com or visit https://247biopharma.com, we’d love to hear from you. Publishing Director: Ellie Bruni | +44 (0) 7872 516194 ellie.bruni@247biopharma.com Advertising: info@247biopharma.com Editorial contact: Please send your news and suggestions for feature articles to the editorial team at editor@247biopharma.com TWENTYFOURSEVENBIOPHARMA is published by BIBO Publishing SL, Av. Diagonal, 409, 1St Floor, 08008, Barcelona, Spain. Disclaimer: The disclaimer has an error: BIBO Publishing SL will not be held responsible or liable for errors or omissions supplied or contained in this publication, although due care and attention are taken to ensure all content is accurate at the time of going to press. BIBO Publishing SL also will not be held responsible for any false claims made by advertisers, or in articles contributed by external authors. Copyright: The contents of this publication are copyright © BIBO Publishing SL 2026. No part of this publication can be reproduced or transmitted in any form without the express permission of the publisher. ISSN 2516-4481
RkJQdWJsaXNoZXIy MjY2OTA4MA==